December 8, 2025Blood

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis finds pediatric iMCD patients show high response rates to siltuximab, suggesting treatment effectiveness alongside prevalent adverse events.

Children with idiopathic multicentric Castleman disease showed higher cha scores compared to adults, indicating greater disease severity.
Eighty-six percent of children treated with siltuximab achieved a clinical response, reflecting similar efficacy to adults.
Observational analysis across two cohorts highlights the need for careful interpretation of pediatric iMCD data.
Increased adverse events, including hyperglycemia and hypertension, were observed in pediatric patients, warranting safety considerations.

Pierson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis finds pediatric iMCD patients show high response rates to siltuximab, suggesting treatment effectiveness alongside prevalent adverse events.